Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-09

Study Completion Date

2025-03-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact. Viruses (rhinovirus, respiratory syncitial virus, influenza virus for the most common) and Streptococcus pneumoniae are the most frequently encountered pathogens. However, more than half of the PACs have no microbiological documentation. The management of CAPs is based on national and international recommendations. Several studies have shown imperfect compliance by clinicians with recommendations with a prognostic impact.

The various published studies insist on the variability of the incidence, the type of pathogen, the severity and the economic impact, depending on the series. They also insist on the need to know the local epidemiology, in particular microbiological, in order to adapt the recommendations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management

NCT07322549

Severe Community-acquired Pneumonia

COMPLETED

Description of Pneumococcal Pneumonia

NCT03322670

Community-acquired Pneumonia

COMPLETED

Innate Immune Response During Community Acquired Pneumonia

NCT03379207

Community-acquired Pneumonia Acute Respiratory Distress Syndrome Innate Immunity

TERMINATED

Community-Acquired Pneumonia : Evaluation of Corticosteroids

NCT02517489

Community Acquired Pneumonia

COMPLETED PHASE3

Etiology of Community Acquired Pneumonia

NCT00471757

Streptococcus Pneumonia Haemophilus Influencae Mycoplasma Pneumonia +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the study is to determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection, Lung Parenchyma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subject (≥ 18 years old),
* acute community-acquired pneumonia (\< 48 hours after admission),
* admitted from the Emergency Department, consultation or home.
* Subject not objecting to the reuse of their data for scientific research purposes

Exclusion Criteria

* Expressed refusal to reuse data for scientific research purposes.
* bronchitis, acute nosocomial pneumopathy, secondary infection due to bronchial dilation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No